Ritholtz Wealth Management Boosts Holdings in Jazz Pharmaceuticals PLC $JAZZ

Ritholtz Wealth Management grew its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 23.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,470 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,937 shares during the period. Ritholtz Wealth Management’s holdings in Jazz Pharmaceuticals were worth $2,698,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Farther Finance Advisors LLC boosted its position in Jazz Pharmaceuticals by 754.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 234 shares in the last quarter. Hantz Financial Services Inc. raised its position in shares of Jazz Pharmaceuticals by 471.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 297 shares in the last quarter. Quent Capital LLC purchased a new position in shares of Jazz Pharmaceuticals in the 3rd quarter valued at approximately $44,000. Geneos Wealth Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Jazz Pharmaceuticals by 30.7% in the third quarter. GAMMA Investing LLC now owns 655 shares of the specialty pharmaceutical company’s stock worth $86,000 after purchasing an additional 154 shares during the period. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $169.41 on Friday. The firm has a market cap of $10.29 billion, a P/E ratio of -27.91, a PEG ratio of 0.75 and a beta of 0.27. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $182.99. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09. The company has a 50 day moving average of $167.01 and a 200 day moving average of $139.74.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, EVP Robert Iannone sold 7,159 shares of the firm’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $168.26, for a total transaction of $1,204,573.34. Following the sale, the executive vice president owned 72,628 shares of the company’s stock, valued at $12,220,387.28. This trade represents a 8.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Patricia Carr sold 5,319 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $182.06, for a total transaction of $968,377.14. Following the transaction, the chief accounting officer directly owned 7,012 shares of the company’s stock, valued at $1,276,604.72. The trade was a 43.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 123,791 shares of company stock worth $21,991,850. 4.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Wall Street Zen raised Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. Piper Sandler reissued an “overweight” rating and set a $219.00 price objective (up previously from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. Needham & Company LLC raised their target price on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Finally, Robert W. Baird lifted their target price on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Thirteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $205.67.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.